Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127181141 | 12718114 | 1 | I | 20141113 | 20150903 | 20160906 | 20160906 | EXP | US-PFIZER INC-3007566 | PFIZER | 17.00 | YR | M | Y | 61.10000 | KG | 20160906 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127181141 | 12718114 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Intravenous (not otherwise specified) | 3000 MG/M2, OVER 3 HOURS ON DAY 1, FREQ: CYCLICAL | UNK | 11719 | 3000 | MG/M**2 | |||||||
| 127181141 | 12718114 | 2 | SS | APREPITANT. | APREPITANT | 1 | UNK | U | 0 | ||||||||||
| 127181141 | 12718114 | 3 | SS | CRIZOTINIB | CRIZOTINIB | 1 | Oral | 165 MG/M2, ON DAYS 1-21; FREQ: 2 DAY; INTERVAL:1 | UNK | 0 | 165 | MG/M**2 | |||||||
| 127181141 | 12718114 | 4 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 200 MG/M2, OVER 15-30 MINUTES ON DAYS 1 AND 5; FREQ: CYCLICAL | UNK | 0 | 200 | MG/M**2 | |||||||
| 127181141 | 12718114 | 5 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 5 MG/M2, ON DAYS 1-5; FREQ: 2 DAY; INTERVAL: 1 | UNK | 0 | 5 | MG/M**2 | |||||||
| 127181141 | 12718114 | 6 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | FREQ: CYCLICAL | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127181141 | 12718114 | 1 | Anaplastic large cell lymphoma T- and null-cell types |
| 127181141 | 12718114 | 2 | Product used for unknown indication |
| 127181141 | 12718114 | 3 | Anaplastic large cell lymphoma T- and null-cell types |
| 127181141 | 12718114 | 4 | Anaplastic large cell lymphoma T- and null-cell types |
| 127181141 | 12718114 | 5 | Anaplastic large cell lymphoma T- and null-cell types |
| 127181141 | 12718114 | 6 | Anaplastic large cell lymphoma T- and null-cell types |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127181141 | 12718114 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127181141 | 12718114 | Oesophagitis | |
| 127181141 | 12718114 | Stomatitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127181141 | 12718114 | 1 | 20141103 | 20141103 | 0 | |
| 127181141 | 12718114 | 3 | 20141103 | 20141120 | 0 | |
| 127181141 | 12718114 | 4 | 20141103 | 20141107 | 0 | |
| 127181141 | 12718114 | 5 | 20141103 | 20141108 | 0 | |
| 127181141 | 12718114 | 6 | 20141106 | 20141107 | 0 |